Kim, J., Park, S., Im, S., Kim, S., Sohn, J., Lee, K. S., . . . Park, Y. H. (2019). Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11). Cancer Commun (Lond).
シカゴスタイル引用形Kim, Ji-Yeon, et al. "Quality of Life Outcomes Including Neuropathy-associated Scale From a Phase II, Multicenter, Randomized Trial of Eribulin Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine As First-line Chemotherapy for HER2-negative Metastatic Breast Cancer: Korean Cancer Study Group Trial (KCSG BR13-11)." Cancer Commun (Lond) 2019.
MLA引用形式Kim, Ji-Yeon, et al. "Quality of Life Outcomes Including Neuropathy-associated Scale From a Phase II, Multicenter, Randomized Trial of Eribulin Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine As First-line Chemotherapy for HER2-negative Metastatic Breast Cancer: Korean Cancer Study Group Trial (KCSG BR13-11)." Cancer Commun (Lond) 2019.